(Rectal Cancer) Nivolumab (Opdivo) After Chemoradiotherapy: VOLTAGE Trial Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- August 19, 2019
- 2 min read
At the ESMO World Congress on Gastrointestinal Cancer (WCGC 2019), held in Barcelona, Spain from July 3–6, 2019, Takayuki Yoshino presented results from the VOLTAGE trial: "Efficacy and safety of nivolumab (anti-PD-1 antibody) monotherapy following preoperative chemoradiotherapy in microsatellite-stable (MSS) resectable locally advanced rectal cancer patients."
Trial Design:
VOLTAGE was a physician-led, open-label, single-arm trial enrolling patients with microsatellite-stable (MSS; Cohort A1, N=39) and high microsatellite instability (MSI-H; Cohort A2, N=2) resectable locally advanced rectal cancer. Following chemoradiotherapy (capecitabine + 50 Gy), patients received nivolumab 240 mg monotherapy every 2 weeks for 5 cycles within 14 days. The primary endpoint was pathological complete response rate (pCR) by independent central review (expected pCR: 30%); secondary endpoints included per-institution pCR and R0 resection rate.
Results (Cohort A1, N=37 evaluable):
- Primary endpoint pCR (independent central review): 30% (11/37 patients)
pCR by PD-L1 expression (MSS group):
- PD-L1 ≥1%: 60%
- PD-L1 <1%: 19%
CD8/eTreg ratio from pre-chemoradiotherapy biopsy correlated with pCR:
- CD8/eTreg ratio ≥2: pCR 62%
- CD8/eTreg ratio <2: pCR 10%
Safety:
Overall adverse event rate: 51.3%. Grade 3–4 adverse events: 7.7%.
Conclusion: Based on the VOLTAGE trial results, Takayuki Yoshino concluded that nivolumab monotherapy following preoperative chemoradiotherapy achieved the primary endpoint of 30% pCR in microsatellite-stable resectable locally advanced rectal cancer patients.
Source: ESMO WCGC 2019
Rectal Cancer | Immunotherapy | Nivolumab | VOLTAGE Trial
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4